Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of UM171-expanded cord blood transplantation in high-risk acute leukemia/myelodysplasia
NL-OMON60405Phase 2Not yet recruiting
- Sponsor
- ExCellThera
- Start
- Nov 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dorocubicel in Acute Leukaemia and myelodysplastic syndrome (MDS), sponsored by ExCellThera. Primary endpoints: Relapse-free survival at 1 year post-transplant, Relapse-free survival at 2 years post-transplant and 1 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
dorocubicel
03
Conditions
Acute Leukaemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON60405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60405.